Gen­fit plans US list­ing as NASH drug­mak­ers race to the fin­ish line

As the race to de­vel­op NASH treat­ments heats up, French drug de­vel­op­er Gen­fit (Eu­ronext: $GN­FT) is plan­ning to list it­self in the Unit­ed States as its drug elafi­bra­nor con­tin­ues to be eval­u­at­ed in a late-stage study for the so far un­treat­ed fat­ty liv­er dis­ease that has rav­aged the de­vel­oped world.

On Mon­day, Gen­fit said it had in­tend­ed to con­duct a reg­is­tered pub­lic of­fer­ing of its or­di­nary shares in the Unit­ed States, in ad­di­tion to a pri­vate place­ment of its or­di­nary shares out­side of the Unit­ed States, pri­mar­i­ly in Eu­rope, in­clud­ing France. The tim­ing, num­ber and price of new or­di­nary shares and Amer­i­can De­posi­tary Shares (ADSs) to be is­sued in the pro­posed pub­lic of­fer­ing and pri­vate place­ment have not yet been de­ter­mined, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER